Blue becomes red: medudoc takes off with new ownership, new team and new platform strategy
medudoc sets a clear turning point after five years of operational market presence. November 2025 not only marks a change of ownership, but also the start of an ambitious scaling agenda. A group of investors led by the make visions Family Office has acquired a majority stake – combined with a substantial injection of capital and a clear mandate: to transform medudoc from a specialist provider of medicolegal educational videos into a comprehensive platform for Patient Education, Informed E-Consent and legally compliant workflow automation in everyday clinical practice.
New chapter, new team, new brand identity
The change of ownership is accompanied by a strategic rebranding process. The previous blue color, which is widely used in the healthcare industry, is giving way to a powerful, modern red – a deliberate signal of dynamism, assertiveness and technological innovation leadership. The medudoc brand is thus positioning itself much more boldly and clearly differentiated from the competition.
At the same time, the management team was expanded in order to consistently drive the next phase of growth. New on board:
- Martin Klässner (CEO)
- Lukas Bauer (CRO)
- Jerolim Filippi (CMO)
The founder Michael Horacek (Ambassador) and the previous managing director and founder Mona Ciotta (COO) will remain operationally involved and ensure technological continuity and the medical technology depth of the product.
From video provider to scalable HealthTech platform
In terms of content, medudoc is undergoing a clear strategic shift. The company is evolving from a producer of individualized medicolegal educational videos to a holistic platform that:
- structured Patient Education digitized and standardized,
- fully digitally maps legally compliant informed consent (e-consent),
- efficiently automates clinical legal and compliance workflows – such as documentation, risk information, language barrier handling or audit preparation.
In this way, medudoc addresses central cost and compliance pain points in everyday clinical practice and positions itself as an end-to-end enabler for legally compliant, patient-centered communication.
Fresh capital for growth and expansion
With the entry of the new investors, the company has been significantly capitalized. The funds will flow directly into product development, platform architecture, regulatory scalability and international market entry. The aim is to establish medudoc as a European standard in digital Patient Education and e-consent automation within the next few years.
Conclusion
The new medudoc is not just a rebranding. It is a strategic relaunch, supported by strong capital, an expanded management team and an ambitious product vision. The new red stands for momentum, courage and maximum focus on impact in everyday clinical practice.
